San Diego-dependent Viking Therapeutics marked itself as a serious competitor inside the weight loss drug sector in February immediately after revealing promising data from the mid-phase demo of experimental drug VK2735, which suggested it rivaled—and outperformed—Novo and Lilly drugs when supplied for a weekly injection and in March the compan